Northern Trust
ELVN icon

Northern Trust’s Enliven Therapeutics ELVN Stock Holding History

Northern Trust’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4M Buy
440,938
+68,622
+18% +$2.91M ﹤0.01% 1737
2026
Q1 		$14.6M Buy
372,316
+20,077
+6% +$556K ﹤0.01% 1867
2025
Q4 		$5.42M Sell
352,239
-42,213
-11% -$841K ﹤0.01% 2425
2025
Q3 		$8.07M Buy
394,452
+69,824
+22% +$1.41M ﹤0.01% 2234
2025
Q2 		$6.51M Sell
324,628
-14,022
-4% -$265K ﹤0.01% 2319
2025
Q1 		$6.66M Buy
338,650
+7,150
+2% +$154K ﹤0.01% 2272
2024
Q4 		$7.46M Buy
331,500
+27,104
+9% +$703K ﹤0.01% 2291
2024
Q3 		$7.77M Buy
304,396
+76,629
+34% +$1.77M ﹤0.01% 2218
2024
Q2 		$5.32M Buy
227,767
+9,009
+4% +$190K ﹤0.01% 2359
2024
Q1 		$3.85M Sell
218,758
-6,054
-3% -$92.9K ﹤0.01% 2630
2023
Q4 		$3.11M Buy
224,812
+30,278
+16% +$370K ﹤0.01% 2750
2023
Q3 		$2.66M Sell
194,534
-1,406
-0.7% -$23.7K ﹤0.01% 2783
2023
Q2 		$4M Buy
+195,940
New +$3.96M ﹤0.01% 2622
2023
Q1 		– Sell
-6,674
Closed -$109K – 4594
2022
Q4 		$109K Buy
6,674
+2,845
+74% +$45.5K ﹤0.01% 4064
2022
Q3 		$35K Hold
3,829
– – ﹤0.01% 4419
2022
Q2 		$19K Hold
3,829
– – ﹤0.01% 4633
2022
Q1 		$29K Hold
3,829
– – ﹤0.01% 4623
2021
Q4 		$34K Hold
3,829
– – ﹤0.01% 4646
2021
Q3 		$62K Buy
+3,829
New +$79.6K ﹤0.01% 4493
2021
Q2 		– Sell
-19,464
Closed -$657K – 4605
2021
Q1 		$657K Sell
19,464
-1,098
-5% -$55.8K ﹤0.01% 3737
2020
Q4 		$1.81M Buy
20,562
+5,292
+35% +$444K ﹤0.01% 3237
2020
Q3 		$1.24M Sell
15,270
-786
-5% -$70.9K ﹤0.01% 3298
2020
Q2 		$1.77M Buy
16,056
+14,408
+874% +$1.61M ﹤0.01% 3100
2020
Q1 		$106K Buy
+1,648
New +$105K ﹤0.01% 3804

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Northern Trust's ELVN Position: Q2 2026 in Review

Northern Trust increased its Enliven Therapeutics (ELVN) stake by 18% in Q2 2026, buying an estimated $2.91M and bringing the position to 440,938 shares worth $22.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1737.

Northern Trust first reported a position in ELVN in Q1 2020 and has held it in 24 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Northern Trust held 440,938 shares of Enliven Therapeutics worth $22.4M as of Q2 2026.
  • Northern Trust bought 68,622 Enliven Therapeutics shares in Q2 2026, an estimated $2.91M.
  • Enliven Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1737 holding.
  • Northern Trust first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.